TITLE:

GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function.

AUTHOR(S):

Odori, Shinji; Hosoda, Kiminori; Tomita, Tsutomu; Fujikura, Junji; Kusakabe, Toru; Kawaguchi, Yoshiya; Doi, Ryuichiro; ... Sakai, Yoshiharu; Uemoto, Shinji; Nakao, Kazuwa

CITATION:

Odori, Shinji ...[et al]. GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function.. Metabolism: clinical and experimental 2013, 62(1): 70-78

ISSUE DATE:

2013-01

URL:

<http://hdl.handle.net/2433/171382>

RIGHT:

© 2013 Elsevier Inc.; この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。; This is not the published version. Please cite only the published version.

***GPR119* expression in normal human tissues and islet cell tumors:
evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and
alpha cells, and involvement in islet function**

Shinji Odori^a, Kiminori Hosoda^{a,*}, Tsutomu Tomita^a, Junji Fujikura^a, Toru Kusakabe^a,
Yoshiya Kawaguchi^b, Ryuichiro Doi^b, Kyoichi Takaori^b, Ken Ebihara^a, Yoshiharu Sakai^b,
Shinji Uemoto^b, and Kazuwa Nakao^a

^aDepartment of Medicine and Clinical Science and ^bDepartment of Surgery,
Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto
606-8507, Japan

* Corresponding author:

Kiminori Hosoda M.D., Ph.D.

Department of Medicine and Clinical Science

Kyoto University Graduate School of Medicine

54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan

Tel: +81-75-751-3172

Fax: +81-75-771-9452

20 E-mail: kh@kuhp.kyoto-u.ac.jp

21

22 Word count of text: 3,192

23 Word count of abstract: 245

24 Number of references: 44

25 Number of tables and figures: 3 and 5, respectively.

26

27 **Funding**

28 This work was supported in part by the Ministry of Education, Culture, Sports, Science
29 and Technology of Japan; Ministry of Health, Labour and Welfare of Japan; Takeda Medical
30 Research Foundation; Smoking Research Foundation; Suzuken Memorial Foundation; Japan
31 Foundation of Applied Enzymology; Novo Nordisk Insulin Research Award; and Lilly
32 Education and Research Grant Office. We gratefully acknowledge the cooperative research
33 program FINDS with Shionogi & Co., Ltd.

34

35 **Conflict of Interest**

36 The authors have no conflict of interest to declare.

37

38 Abstract

39 **Objective** GPR119 is reportedly involved in regulating glucose metabolism and food intake in
40 rodents, but little is known about its expression and functional significance in humans. To
41 begin to assess the potential clinical importance of GPR119, was examined the distribution of
42 *GPR119* gene expression in humans. **Materials/Methods** Expression of GPR119 mRNA in
43 fresh samples of normal human pancreas ($n=19$) and pancreatic islets ($n=3$) and in
44 insulinomas ($n=2$) and glucagonomas ($n=2$), all collected at surgery, were compared with the
45 mRNA expression of various receptors highly expressed and operative in human pancreatic
46 islets. **Results** GPR119 mRNA was most abundant in the pancreas, followed by the
47 duodenum, stomach, jejunum, ileum and colon. Pancreatic levels of GPR119 mRNA were
48 similar to those of GPR40 mRNA and were higher than those of GLP1R and SUR1 mRNA,
49 which are strongly expressed in human pancreatic islets. Moreover, levels of GPR119 mRNA
50 in pancreatic islets were more than 10 times higher than in adjacent pancreatic tissue, as were
51 levels of *GPR40* mRNA. GPR119 mRNA was also abundant in two cases of insulinoma and
52 two cases of glucagonoma, but was undetectable in a pancreatic acinar cell tumor. Similar
53 results were obtained with mouse pancreatic islets, MIN6 insulinoma cells and alpha-TC
54 glucagonoma cells. **Conclusions** The results provide evidence of an islet-gastrointestinal
55 distribution of GPR119, its expression in pancreatic beta and alpha cells, and its possible

56 involvement in islet function. They also provide the basis for a better understanding of the
57 potential clinical importance of GPR119.

58

59 **Keywords** insulinoma, glucagonoma, insulin secretion, gastrointestinal hormones

60

61

62 **Abbreviations** FFPE: formalin-fixed, paraffin-embedded. GLP1R: glucagon-like peptide 1

63 receptor. GPR119: G protein-coupled receptor 119. GPR40: G protein-coupled receptor 40.

64 SUR1: sulfonylurea receptor 1

1. Introduction

Endogenous lipids such as free fatty acids and acylethanolamides are known to regulate glucose metabolism and food intake [1-3]. The underlying molecular mechanisms are not fully understood, however. Recently, four orphan G protein-coupled receptors (GPR40, GPR41, GPR43 and GPR120) were deorphaned and identified as fatty acid receptors [4-8]. Among those, we found that GPR40 is highly expressed in human pancreatic beta cells and is involved in regulating insulin secretion [9, 10]. In addition, GPR119 has been identified as a Gs-coupled receptor whose putative endogenous ligands include oleoylethanolamide (OEA) [11, 12] and possibly other lipids [13-16]. *In vitro* studies have implicated GPR119 in the regulation of insulin and incretin secretion [12, 14, 15, 17-20], and *in vivo* studies in rats and mice suggest its involvement in the regulation of glucose metabolism and feeding [11, 14, 18, 19, 21-30]. That said, glucose metabolism in humans and mice may differ [31], and little is known about the expression and physiological significance of GPR119 in humans.

In that context, we examined *GPR119* gene expression in various human tissues, including fresh samples of pancreas and digestive tract collected at surgery. In addition, to gain further insight into the localization of GPR119 within the human pancreas, we compared *GPR119* expression in human pancreatic islets and adjacent pancreatic tissue, as well as in insulinomas and glucagonomas, two very rare human tumors that possess the endocrine properties of pancreatic beta and alpha cells, respectively. The results provide evidence of the

- 84 islet-gastrointestinal distribution of GPR119, its expression in pancreatic beta and alpha cells,
- 85 and its possible involvement in islet function in humans.

2. Methods

2.1. Subjects, tissue sampling and pancreatic islet isolation

The clinical profiles of all patients enrolled in the present study are shown in Table 1. The study was performed in accordance with the Declaration of Helsinki and approved by the Ethical Committee on Human Research of Kyoto University Graduate School of Medicine. Signed informed consent was obtained from all patients.

Normal human cerebral tissues ($n=3$) were collected from three patients at autopsy; one had died from amyotrophic lateral sclerosis, one from an iliopsoas muscle tumor and one from a ruptured aortic aneurysm. Normal tissues from the pancreas ($n=19$), esophagus ($n=3$), stomach ($n=3$), duodenum ($n=3$), jejunum ($n=3$), ileum ($n=2$), colon ($n=3$) and liver ($n=2$) were collected from 23 patients at tumor resection. In Fig. 1b and c, pancreatic tissues from four patients (patients 9, 10, 13 and 19 in Tables 1 and 2) were analyzed because of the limited amount of total RNA extracted from each patient. In all cases, sample margins contained no sign of tumor invasion, so the samples were considered to be tumor-free. In addition, samples of insulinoma ($n=2$), glucagonoma ($n=1$) and a pancreatic acinar cell tumor ($n=1$) were collected at surgery. From another patient with a glucagonoma, samples of normal pancreatic tissue and glucagonoma were obtained as formalin-fixed, paraffin-embedded (FFPE) sections. Islets were promptly isolated from pancreatic samples using the mince method and were collected manually using a stereomicroscope [9, 10]. In Japan, HbA1c is

measured using high-performance liquid chromatography with a set of calibrators assigned by the Japan Diabetes Society (normal range 4.3-5.8%). A correlational analysis showed that, in Japan, estimated HbA1c values are 0.4% lower than those measured by the National Glycohemoglobin Standardization Program (NGSP) [32]. For that reason, we standardized the obtained HbA1c values to NGSP units by adding 0.4% to the measured values.

2.2. Preparation and culture of mouse pancreatic islets, the MIN6 mouse insulinoma cell line and the alpha-TC mouse glucagonoma cell line

Male 14-week-old C57BL/6 mice were purchased from Japan SLC (Shizuoka, Japan) and housed in a temperature-, humidity- and light-controlled room with free access to water and standard chow (Nosan Corporation, Kanagawa, Japan). Mouse pancreatic islets were isolated as previously described [33]. All experimental procedures were approved by the Animal Research Committee, Kyoto University Graduate School of Medicine, and were performed in accordance with institutional and national guidelines for animal experimentation. MIN6 cells were kindly provided by Dr. Junichi Miyazaki [34], and alpha-TC cells were obtained from American Type Culture Collection (ATCC) (Manassas, VA, USA). MIN6 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 15% FBS, while alpha-TC cells were maintained in RPMI 1640 medium supplemented with 10% FBS. Both media also contained 100 units/ml penicillin and 0.1 mg/ml streptomycin (Life Technologies

124 Japan, Tokyo, Japan). The cells were incubated at 37°C under an atmosphere of humidified
125 air (95%) and CO₂ (5%).

126

127 **2.3. Total RNA preparation and cDNA synthesis**

128 Total RNAs were extracted from fresh tissues and cell lines using QIAGEN RNeasy Mini
129 Kits [9, 10, 33], and from FFPE tissue sections using QIAGEN RNeasy FFPE Kits (QIAGEN
130 K.K., Tokyo, Japan). The collected RNA was then treated with DNase I to remove any
131 contaminating DNA. Additionally, total RNAs from human brain, thyroid, heart, lung,
132 trachea, kidney, esophagus, liver, skeletal muscle, adipose tissue, spleen, bladder, prostate,
133 placenta and cervix were obtained from Life Technologies Japan. Total RNAs from stomach,
134 small intestine, colon, pancreas, testis, ovary and uterus were from Takara Clontech (Tokyo,
135 Japan). Finally, total RNAs from hypothalamus were obtained from two sources, Life
136 Technologies Japan and BioChain Institute (Hayward, CA, USA). First strand cDNA was
137 synthesized by random hexamer-primed reverse transcription using SuperScript II reverse
138 transcriptase (Life Technologies Japan).

139

140 **2.4. Quantification of human and mouse receptor gene expression**

141 Levels of GPR119 mRNA in the pancreas and pancreatic islets were compared with those of
142 GPR40, the glucagon-like peptide-1 receptor (GLP1R) and the sulfonylurea receptor 1

(ABCC8 or SUR1) mRNA, which are reportedly expressed in human pancreatic islets and involved in insulin secretion [9, 10]. Messenger RNA levels were quantified using the TaqMan PCR method with an ABI PRISM 7700 Sequence Detector (Life Technologies Japan), as described previously [9, 10]. To estimate the copy number of each mRNA, standard curves were generated using oligo DNA fragments (Sigma Genosys Japan, Tokyo, Japan) containing the PCR amplicon region. The receptor mRNA levels were normalized to the level of GAPDH mRNA and expressed as the receptor/GAPDH [copy/copy] ratio [9]. The sequences of the primers and probes (Life Technologies Japan) used for the quantification of the mRNAs were as follows: human *GPR119* (NM_178471), CCATGGCTGGAGGTTATCGA (forward), GCTCCCAATGAGAACAGACACA (reverse) and 6-carboxyfluorescein (FAM)-CCCCACGGACTCCCAGCGACT-6-carboxytetramethylrhodamine (TAMRA) (probe); mouse *GPR119* (NM_181751), TCCAGAGAGGACCAGAGAAAGC (forward), GCAGCGTCTTAGCCATCGA (reverse) and FAM-TCACATCGTCACTATCAGCCATCCGG-TAMRA (probe); mouse *GPR40* (NM_194057), GGCTTTCCATTGAACTTGTTAGC (forward), CCCAGATGGAGAGTGTAGACCAA (reverse) and FAM-TGTCCCACGCTAAACTGCGACTCACTC-TAMRA (probe); mouse *GADPH* (NM_008084), TCCATGCCATCACTGCCA (forward), GCCCCACGGCCATCA (reverse)

and FAM-CAGAAGACTGTGGATGGCCCCTC-TAMRA (probe). The sequences of the primers and probes used for quantification of the human GPR40, GLP1R, ABCC8 (SUR1) and GAPDH mRNAs are described elsewhere [9, 10].

2.5. Data analysis on metabolic parameters

We evaluated beta cell function and systemic insulin resistance using the insulinogenic index ($n=10$) [35] or the homeostasis model assessment of beta cell function (HOMA-beta) ($n=14$) and insulin resistance (HOMA-IR) ($n=14$) [36], respectively. The difference between the numbers of patients whose test data were included in the HOMA indices and insulinogenic index reflects the availability of data for plasma glucose and serum insulin levels at the 30 min mark during the oral glucose tolerance test (OGTT). The area under the serum insulin concentration-time curve (insulin AUC) was calculated from the OGTT data using the trapezoidal rule. Patients 7, 12 and 17 were excluded from analysis of the correlation between pancreatic GPR119 mRNA levels and metabolic parameters, because of a diagnosis of insulinoma (patient 7) or percutaneous transhepatic biliary drainage (patients 12 and 17). None of the patients were treated with oral glucose-lowering agents or with insulin. Table 2 shows the metabolic parameters of the patients whose pancreatic tissues were examined; the patient numbers correspond to those in Table 1.

181 **2.6. Statistical analysis**

182 Correlations between pancreatic GPR119 mRNA levels and clinical parameters were
183 examined using the simple regression analysis. Differences between groups were assessed
184 using unpaired two-tailed *t*-tests or ANOVA where applicable. Values of $p < 0.05$ were
185 considered significant (Statcel, Social Research Information, Tokyo, Japan).

3. Results

3.1 Expression of GPR119 mRNA in normal human tissues

We initially tested for GPR119 mRNA in samples of commercially available total RNA from normal human tissues. We found that the transcript was most abundant in the pancreas, followed by the gastrointestinal tract (small intestine, colon and stomach) and the testis (Fig. 1A). GPR119 mRNA was not detected in any other human tissue tested. To gain further insight into *GPR119* gene expression humans and verify the aforementioned distribution profile, we also examined tissues obtained at surgery or autopsy. Among those samples, GPR119 mRNA was most abundant in the pancreas, followed by the duodenum, stomach, jejunum, ileum and colon, but was not detected in the esophagus, liver or cerebrum (Fig. 1B).

3.2 Expression of GPR119, GPR40, GLP1R and SUR1 mRNAs in the human pancreas

Using specimens from four patients, we compared the pancreatic expression of GPR119 mRNA with that of GPR40, GLP1R and SUR1 mRNA in the same samples. We found that pancreatic levels of GPR119 mRNA were comparable to those of GPR40 mRNA and were higher than those of GLP1R and SUR1 mRNA (Fig. 1C).

3.3. Expression of GPR119 and GPR40 mRNA in isolated pancreatic islets and adjacent pancreatic tissue

We next assessed *GPR119* expression in pancreatic islets from three patients (Fig. 2A). Levels of GPR119 mRNA in freshly isolated islets were approximately 13 to 16 times higher than in the adjacent pancreatic tissue from the same patients. We also analyzed *GPR40* expression and found that levels of GPR119 and GPR40 mRNA were similar in isolated pancreatic islets (Fig. 2B).

3.4. Expression of GPR119 and GPR40 mRNA in human insulinomas and glucagonomas

We also assessed expression of GPR119 and GPR40 mRNA using total RNAs extracted from specimens of fresh insulinomas ($n=2$), a glucagonoma ($n=1$) and a pancreatic acinar cell tumor ($n=1$), as well as from FFPE glucagonoma tissue sections from another patient ($n=1$). In the two cases of insulinoma, tumoral GPR119 mRNA levels were comparable to those in pancreatic islets (Fig. 3A). A considerable amount of GPR119 mRNA was also detected in tissue extracts from the glucagonoma (Fig. 3A), where GPR40 mRNA was not detectable (Fig. 3C). Levels of GPR119 mRNA in tissue extracts from FFPE sections of non-tumor pancreas and glucagonoma were similar to those in the corresponding specimens collected at surgery (Fig. 3, A and B). GPR40 mRNA was not detected in extracts from the same FFPE

glucagonoma sections (Fig. 3D), which is consistent with the level in the fresh tumor specimen (Fig. 3, C and D). Neither GPR119 nor GPR40 mRNAs was detectable in the acinar cell tumor specimen (Fig. 3, A and C).

3.5. Expression of GPR119 and GPR40 mRNAs in mouse pancreatic islets, MIN6 insulinoma cells and alpha-TC glucagonoma cells

To further explore *GPR119* expression in pancreatic islet cells, we measured GPR119 mRNA levels in mouse pancreatic islets, MIN6 insulinoma cells and alpha-TC glucagonoma cells. We also assessed expression of GPR40 mRNA in the same samples, as GPR40 is known to be preferentially expressed in pancreatic beta cells in both rodents and humans [4, 9, 10, 37]. High levels of GPR119 mRNA, comparable to those of GPR40 mRNA, were detected in mouse pancreatic islets (Fig. 4, A and B). Likewise, similar levels of GPR119 and GPR40 mRNA were detected in MIN6 cells (Fig. 4, A and B). On the other hand, the level of GPR119 mRNA in alpha-TC cells was approximately 1/7 that in MIN6 cells, and no GPR40 mRNA was detected in alpha-TC cells (Fig. 4, A and B).

3.6. Correlation between pancreatic GPR119 mRNA expression and the insulinogenic index and HOMA-beta in humans

To investigate the functional implications of pancreatic GPR119 expression in humans, we

initially assessed GPR119 mRNA expression in non-tumor pancreatic tissue samples from 19 patients with various pancreatic tumors (Table 1). High levels of GPR119 mRNA, comparable to those in the four cases summarized in Fig 1, A and B (0.336 ± 0.037 vs. 0.319 ± 0.090), were detected in all of the tissue samples analyzed (Table 2). Because the inter-individual variation in the pancreatic GPR119 mRNA level ($n=19$) was high, to begin to explore the physiological importance of GPR119 in humans, we evaluated the relationship between pancreatic GPR119 mRNA levels and various clinical parameters. We found that GPR119 mRNA expression did not significantly differ among the head, body and tail portions of the pancreas (Table 3), nor did it correlate significantly with age (Supplemental Table S1).

When we then evaluated the correlation between pancreatic *GPR119* gene expression and several metabolic parameters, including glucose and triglyceride metabolism (Table 2), we found that pancreatic GPR119 mRNA levels did not correlate significantly with BMI, fasting plasma glucose (FPG), 2-h post-OGTT plasma glucose (2h-PG), insulin AUC or fasting serum triglyceride levels (Supplemental Table S1), nor did they correlate significantly with HbA1c levels or HOMA-IR values (Supplemental Table S1, Fig. 5, A and B). By contrast, pancreatic GPR119 mRNA levels positively and significantly correlated with the insulinogenic index ($n=10$, $p=0.004$, $r=0.817$) (Fig. 5C) and with HOMA-beta values ($n=14$, $p=0.043$, $r=0.547$) (Fig. 5D). Using the same patient data used to calculate the insulinogenic index ($n=10$) and HOMA-beta ($n=14$), we also tested for correlations between GPR119

261 mRNA expression and HbA1c levels and HOMA-IR values, which confirmed the absence of

262 a significant correlation (Supplemental Table S1).

263

4. Discussion

Our findings demonstrate for the first time that *GPR119* is highly expressed in human pancreatic islets, where the level of *GPR119* expression is enriched more than 10-fold, as compared to adjacent areas of the pancreas in the same individuals. We also found that pancreatic levels of *GPR119* mRNA are similar to those of *GPR40* mRNA and are higher than those of *GLP1R* and *SUR1* mRNA. Likewise, the level of *GPR119* mRNA in isolated pancreatic islets is similar to that of *GPR40* mRNA and higher than those of *SUR1* and *GLP1R* mRNA [9, 10]. This is noteworthy, as these receptors are reported to be abundantly expressed in human pancreatic islets.

We observed that substantial amounts of *GPR119* mRNA are expressed in human insulinomas ($n=2$) and glucagonomas ($n=2$), and that the tumoral levels of the transcript are comparable to those in pancreatic islets. A similar pattern of *GPR119* mRNA expression was also detected with mouse pancreatic islets, MIN6 insulinoma cells and alpha-TC glucagonoma cells. Thus *GPR119* appears to be highly expressed in both beta and alpha cells in human and mouse pancreatic islets. Moreover, our observation that the expression levels of *GPR119* and *GPR40* mRNAs in human pancreatic islets are similar and are higher than that of *SUR1* mRNA is noteworthy because *SUR1* is reported to be abundantly expressed in both beta and alpha cells and is involved in the regulation of islet function, including insulin and glucagon secretion [38-40]. This strong expression suggests *GPR119* may be involved in

283 pancreatic islet function in humans. Consistent with that idea, pancreatic GPR119 mRNA
284 levels correlated positively with two indices of beta cell function: the insulinogenic index and
285 the HOMA-beta. Collectively, therefore, the present findings provide evidence for the
286 possible involvement of GPR119 in islet function, perhaps affecting insulin secretion.

287 Using fresh tissue samples collected at surgery, we observed that, in humans, GPR119
288 mRNA is abundantly expressed in the small intestine, stomach and colon, but not in the
289 esophagus. In rodents, GPR119 appears to be expressed in enteroendocrine cells, including L
290 and K cells, and to be involved in the regulation of incretin and polypeptide YY secretion. In
291 humans, enteroendocrine cells are distributed throughout the gastrointestinal tract, but not in
292 the esophagus. Although details of GPR119 expression and its function in the human
293 gastrointestinal tract will require further investigation, our findings are consistent with the
294 idea that GPR119 is expressed in enteroendocrine cells and is involved in incretin and peptide
295 YY secretion.

296 We detected no GPR119 mRNA in the human hypothalamus, brain or cerebrum, which
297 is consistent with a recent report that GPR119 mRNA is not significantly expressed in the
298 human brain or hypothalamus [19]. Although earlier reports using OEA (a putative GPR119
299 ligand) and a synthetic OEA analogue in rats suggest GPR119 may mediate signalling
300 leading to reduced food intake and body weight, OEA appears to act mainly in peripheral
301 tissues, rather than in the central nervous system [41]. Our finding that GPR119 mRNA is

highly expressed in the human stomach and duodenum is consistent with the notion that GPR119 is involved in regulating food intake in humans, as the bipolar vagal afferents involved in regulating feeding are known to project to the stomach and upper intestine [42, 43].

In summary, the present study demonstrates that, in humans, GPR119 mRNA is abundantly expressed in healthy pancreatic islets and the human gastrointestinal tract, and in insulinomas and glucagonomas. The results provide evidence of an islet-gastrointestinal distribution of GPR119, its expression in pancreatic beta and alpha cells, and its possible involvement in islet function. They also provide the basis for a better understanding of the potential clinical importance of GPR119.

4.1. Limitations of the present study

Our study has several limitations that should be noted.

1. To our knowledge, no specific antibody against human GPR119 is available, so we were unable to assess expression of GPR119 protein.
2. The enrolled subjects were tumor-bearing patients, though the tumors were at an early stage or benign, and were resectable. Pancreatic biopsy is rarely performed because of the risk of pancreatitis, and is not justified in those without severe illness [44].

Therefore, we analyzed human pancreatic tissues collected during surgery. Because

pancreatic tissue is very vulnerable to postmortem autolysis, specimens obtained at surgery offer substantial advantages for precise analysis of *GPR119* expression. Nonetheless, possible weight loss and the paracrine effects of pancreatic cancer cells on beta cells could have influenced the correlation study.

3. Patients enrolled in the present study were not severely diabetic (HbA1c was less than 7.2%), nor were they overweight or obese (BMIs were less than 25). Thus clarification of the pathophysiological role of GPR119 in human diabetes and obesity must await further investigation in patients with a wider range of glucose tolerances and BMIs.
4. Plasma glucagon levels were not determined in the preoperative evaluation, and were not included in the present study. Beta cell mass is known to be much greater than alpha cell mass in pancreatic islets, and correlations between GPR119 mRNA levels and indices for beta cell function seem plausible, but may underestimate the involvement of GPR119 in the glucagon secretion. Further studies will be necessary to clarify the role of GPR119 in glucagon secretion.

336 **Funding**

337 This work was supported in part by the Ministry of Education, Culture, Sports, Science
338 and Technology of Japan; Ministry of Health, Labor and Welfare of Japan; Takeda Medical
339 Research Foundation; Smoking Research Foundation; Suzuken Memorial Foundation; Japan
340 Foundation of Applied Enzymology; Novo Nordisk Insulin Research award; and Lilly
341 Education and Research Grant Office. We gratefully acknowledge cooperative research
342 program FINDS with Shionogi & Co., Ltd.

343

344 **Acknowledgement**

345 The authors acknowledge the technical assistance of Ms. A. Ryu of Kyoto University
346 Graduate School of Medicine.

347

348 **Conflict of Interest**

349 The authors have no conflict of interest to declare.

350

351 **Author contributions:**

352 SO: data collection and analysis, data interpretation, manuscript writing. KH: data
353 interpretation, manuscript writing. TT: data analysis, data interpretation, manuscript writing.
354 JF, TK and KE: data interpretation, manuscript writing. YK, RD, KT, YS and SU: data

355 collection, data interpretation. KN: data interpretation, manuscript writing.

Figure Legends

Fig. 1 - Expression of GPR119 mRNA in human tissues. All receptor mRNA levels were normalized to the level of GAPDH mRNA in the same tissue. A, GPR119 mRNA levels in commercially obtained samples of human total RNA from the indicated tissues. B, GPR119 mRNA expression in the indicated human tissues collected at autopsy (cerebrum) or at surgery (all tissues except cerebrum). C, Expression of GPR119, GPR40, GLP1R and SUR1 mRNA in normal human pancreatic tissue collected at surgery ($n=4$). The specimens used were the same as in panel B. Receptor mRNA levels in panels B and C are expressed as means $\pm$ SEM. *Black bar*, GPR119; *white bar*, GPR40; *hatched bar*, GLP1R; *double-hatched bar*, ABCC8 (SUR1).

Fig. 2 - Expression of GPR119 mRNA in human pancreatic islets and adjacent pancreatic tissue. All receptor mRNA levels were normalized to the level of GAPDH mRNA in the same tissue. A, Comparison of GPR119 mRNA expression in pancreatic islets and adjacent pancreatic tissue from three patients. *White bars*, pancreas; *black bars*, pancreatic islets. B, Comparison of GPR119 and GPR40 mRNA expression in pancreatic islets and adjacent pancreatic tissue. The tissue samples used were the same as in panel A ($n=3$). Levels of GPR119 and GPR40 mRNA are expressed as means $\pm$ SEM. *White bars*, pancreas; *black bars*, pancreatic islets.

375

376 Fig. 3 - Expression of GPR119 and GPR40 mRNA in human pancreatic islets, insulinomas
377 and glucagonomas. A and C, Expression of GPR119 (A) and GPR40 (C) mRNA in non-tumor
378 pancreas (Pancreas), pancreatic islets (Islets), insulinomas (INS), a glucagonoma (GLU) and
379 a pancreatic acinar cell tumor (ACI). B and D, Expression of GPR119 (B) and GPR40 (D)
380 mRNA in extracts from non-tumor pancreatic and glucagonoma tissue sections ($n=1$ each).
381 All receptor mRNA levels were normalized to the level of GAPDH mRNA in the same tissue.
382 GPR119 and GPR40 mRNA levels in pancreas and pancreatic islets are expressed as means $\pm$
383 SEM. *White bars*, pancreas; *black bars*, pancreatic islets; *hatched bars*, insulinomas;
384 *double-hatched bars*, glucagonomas.

385

386 Fig. 4 - Expression of GPR119 and GPR40 mRNAs in mouse pancreatic islets, insulinoma
387 and glucagonoma. Expression of GPR119 (A) and GPR40 (B) mRNAs pancreatic islets,
388 MIN6 insulinoma cells and alpha-TC glucagonoma cells. All receptor mRNA levels were
389 normalized to the level of GAPDH mRNA in the same tissue. *Black bars*, pancreatic islets;
390 *hatched bars*, MIN6 cells; *double hatched bars*, alpha-TC cells.

391

392 Fig. 5 - Correlations between human pancreatic GPR119 mRNA levels and parameters of
393 glucose metabolism, including HbA1c levels ($n=16$) (A), HOMA-IR values ($n=14$) (B), the

394 insulinogenic index ($n=10$) (C) and HOMA-beta values ($n=14$) (D). All GPR119 mRNA
395 levels were normalized to the level of GAPDH mRNA in the same tissue. Simple regression
396 analysis was used to determine p and r values. The solid lines are regression lines.

- 397 1 Stein DT, Stevenson BE, Chester MW, et al. The insulinotropic potency of fatty acids is
398 influenced profoundly by their chain length and degree of saturation. *J Clin Invest*
399 1997;100(2):398-403.
- 400 2 Lam TK, Pocai A, Gutierrez-Juarez R, et al. Hypothalamic sensing of circulating fatty acids
401 is required for glucose homeostasis. *Nat Med* 2005;11(3):320-7.
- 402 3 Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight
403 through activation of the nuclear receptor PPAR-alpha. *Nature* 2003;425(6953):90-3.
- 404 4 Itoh Y, Kawamata Y, Harada M, et al. Free fatty acids regulate insulin secretion from
405 pancreatic beta cells through GPR40. *Nature* 2003;422(6928):173-6.
- 406 5 Brown AJ, Goldsworthy SM, Barnes AA, et al. The Orphan G protein-coupled receptors
407 GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J Biol*
408 *Chem* 2003;278(13):11312-9.
- 409 6 Hirasawa A, Tsumaya K, Awaji T, et al. Free fatty acids regulate gut incretin glucagon-like
410 peptide-1 secretion through GPR120. *Nat Med* 2005;11(1):90-4.
- 411 7 Ahren B. Islet G protein-coupled receptors as potential targets for treatment of type 2
412 diabetes. *Nat Rev Drug Discov* 2009;8(5):369-85.
- 413 8 Kebede MA, Alquier T, Latour MG, et al. Lipid receptors and islet function: therapeutic
414 implications? *Diabetes Obes Metab* 2009;11 Suppl 4:10-20.
- 415 9 Tomita T, Masuzaki H, Iwakura H, et al. Expression of the gene for a membrane-bound
416 fatty acid receptor in the pancreas and islet cell tumours in humans: evidence for GPR40
417 expression in pancreatic beta cells and implications for insulin secretion. *Diabetologia*
418 2006;49(5):962-8.
- 419 10 Tomita T, Masuzaki H, Noguchi M, et al. GPR40 gene expression in human pancreas and
420 insulinoma. *Biochem Biophys Res Commun* 2005;338(4):1788-90.
- 421 11 Overton HA, Babbs AJ, Doel SM, et al. Deorphanization of a G protein-coupled receptor
422 for oleylethanolamide and its use in the discovery of small-molecule hypophagic agents.
423 *Cell Metab* 2006;3(3):167-75.
- 424 12 Lauffer LM, Iakubov R, Brubaker PL. GPR119 is essential for
425 oleylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal
426 enteroendocrine L-cell. *Diabetes* 2009;58(5):1058-66.
- 427 13 Hansen KB, Rosenkilde MM, Knop FK, et al. 2-Oleoyl glycerol is a GPR119 agonist and
428 signals GLP-1 release in humans. *J Clin Endocrinol Metab* 2011;96(9):E1409-17 doi:
429 10.1210/jc.2011-0647.
- 430 14 Chu ZL, Carroll C, Chen R, et al. N-oleoyldopamine enhances glucose homeostasis
431 through the activation of GPR119. *Mol Endocrinol* 2010;24(1):161-70 doi:

- 10.1210/me.2009-0239.
- 15 Soga T, Ohishi T, Matsui T, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. *Biochem Biophys Res Commun* 2005;326(4):744-51.
- 16 Kogure R, Toyama K, Hiyamuta S, et al. 5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion. *Biochem Biophys Res Commun* 2011;416(1-2):58-63 doi: 10.1016/j.bbrc.2011.10.141.
- 17 Ning Y, O'Neill K, Lan H, et al. Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells. *Br J Pharmacol* 2008;155(7):1056-65.
- 18 Chu ZL, Jones RM, He H, et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. *Endocrinology* 2007;148(6):2601-9.
- 19 Chu ZL, Carroll C, Alfonso J, et al. A role for intestinal endocrine cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. *Endocrinology* 2008;149(5):2038-47.
- 20 Lan H, Lin HV, Wang CF, et al. Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. *Br J Pharmacol* 2012;165(8):2799-807 doi: 10.1111/j.1476-5381.2011.01754.x; 10.1111/j.1476-5381.2011.01754.x.
- 21 Semple G, Fioravanti B, Pereira G, et al. Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119. *J Med Chem* 2008;51(17):5172-5.
- 22 Lan H, Vassileva G, Corona A, et al. GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis. *J Endocrinol* 2009;201(2):219-30.
- 23 Gao J, Tian L, Weng G, et al. Stimulating beta-cell replication and improving islet graft function by AR231453, A gpr119 agonist. *Transplant Proc* 2011;43(9):3217-20 doi: 10.1016/j.transproceed.2011.10.021.
- 24 Flock G, Holland D, Seino Y, et al. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. *Endocrinology* 2011;152(2):374-83.
- 25 Semple G, Ren A, Fioravanti B, et al. Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control. *Bioorg Med Chem Lett* 2011;21(10):3134-41 doi: 10.1016/j.bmcl.2011.03.007.
- 26 Semple G, Lehmann J, Wong A, et al. Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. *Bioorg Med Chem Lett* 2011; doi: 10.1016/j.bmcl.2011.12.092.

- 470 27 Yoshida S, Ohishi T, Matsui T, et al. The role of small molecule GPR119 agonist,
471 AS1535907, in glucose-stimulated insulin secretion and pancreatic beta-cell function.
472 *Diabetes Obes Metab* 2011;13(1):34-41 doi: 10.1111/j.1463-1326.2010.01315.x;
473 10.1111/j.1463-1326.2010.01315.x.
- 474 28 Cox HM, Tough IR, Woolston AM, et al. Peptide YY is critical for acylethanolamine
475 receptor Gpr119-induced activation of gastrointestinal mucosal responses. *Cell Metab*
476 2010;11(6):532-42 doi: 10.1016/j.cmet.2010.04.014.
- 477 29 Katz LB, Gambale JJ, Rothenberg PL, et al. Pharmacokinetics, pharmacodynamics, safety,
478 and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes
479 agent, in healthy male subjects. *Clin Pharmacol Ther* 2011;90(5):685-92 doi:
480 10.1038/clpt.2011.169; 10.1038/clpt.2011.169.
- 481 30 Katz LB, Gambale JJ, Rothenberg PL, et al. Effects of JNJ-38431055, a novel GPR119
482 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with
483 type 2 diabetes. *Diabetes Obes Metab* 2012; doi: 10.1111/j.1463-1326.2012.01587.x;
484 10.1111/j.1463-1326.2012.01587.x.
- 485 31 Vassilopoulos S, Esk C, Hoshino S, et al. A role for the CHC22 clathrin heavy-chain
486 isoform in human glucose metabolism. *Science* 2009;324(5931):1192-6.
- 487 32 Seino Y, Nanjo K, Tajima N, et al. Report of the Committee on the classification and
488 diagnostic criteria of diabetes mellitus. *Diabetol Int* 2010;1:2-20.
- 489 33 Iwakura H, Hosoda K, Son C, et al. Analysis of rat insulin II promoter-ghrelin transgenic
490 mice and rat glucagon promoter-ghrelin transgenic mice. *J Biol Chem*
491 2005;280(15):15247-56.
- 492 34 Miyazaki J, Araki K, Yamato E, et al. Establishment of a pancreatic beta cell line that
493 retains glucose-inducible insulin secretion: special reference to expression of glucose
494 transporter isoforms. *Endocrinology* 1990;127(1):126-32.
- 495 35 Ferrannini E, Gastaldelli A, Miyazaki Y, et al. beta-Cell function in subjects spanning the
496 range from normal glucose tolerance to overt diabetes: a new analysis. *J Clin Endocrinol*
497 *Metab* 2005;90(1):493-500.
- 498 36 Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin
499 resistance and beta-cell function from fasting plasma glucose and insulin concentrations in
500 man. *Diabetologia* 1985;28(7):412-9.
- 501 37 Briscoe CP, Tadayyon M, Andrews JL, et al. The orphan G protein-coupled receptor
502 GPR40 is activated by medium and long chain fatty acids. *J Biol Chem*
503 2003;278(13):11303-11.
- 504 38 Rajan AS, Aguilar-Bryan L, Nelson DA, et al. Sulfonylurea receptors and ATP-sensitive
505 K⁺ channels in clonal pancreatic alpha cells. Evidence for two high affinity sulfonylurea
506 receptors. *J Biol Chem* 1993;268(20):15221-8.
- 507 39 Gribble FM, Reimann F. Sulphonylurea action revisited: the post-cloning era.

508 *Diabetologia* 2003;46(7):875-91.
509 40 Cooperberg BA, Cryer PE. Beta-cell-mediated signaling predominates over direct
510 alpha-cell signaling in the regulation of glucagon secretion in humans. *Diabetes Care*
511 2009;32(12):2275-80.
512 41 Rodriguez de Fonseca F, Navarro M, Gomez R, et al. An anorexic lipid mediator regulated
513 by feeding. *Nature* 2001;414(6860):209-12.
514 42 Dockray GJ. The versatility of the vagus. *Physiol Behav* 2009;97(5):531-6.
515 43 Engelstoft MS, Egerod KL, Holst B, et al. A gut feeling for obesity: 7TM sensors on
516 enteroendocrine cells. *Cell Metab* 2008;8(6):447-9.
517 44 Imagawa A, Hanafusa T, Uchigata Y, et al. Different contribution of class II HLA in
518 fulminant and typical autoimmune type 1 diabetes mellitus. *Diabetologia*
519 2005;48(2):294-300.

Table 1. Clinical profiles of the patients who underwent pancreatectomy and tissues analyzed

Patient	Age(years)	Sex(M/F)	Disease	Tissue analyzed
1	26	M	Pancreatic cancer	Pancreas (tail)
2	47	F	Pancreatic cancer	Pancreas (head)
3	53	F	Pancreatic cancer	Pancreas (head)
4	54	M	Pancreatic cancer	Pancreas (head)
5	55	F	Pancreatic cancer	Pancreas (body)
6	57	M	Islet cell tumor (nonfunctional)	Pancreas (tail)
7	59	F	Insulinoma	Pancreas (head), insulinoma
8	60	M	Pancreatic cancer	Pancreas (body)
9	60	M	Pancreatic cancer	Pancreas (head)
10	61	F	Papilla cancer	Pancreas (head)
11	63	F	Islet cell tumor (nonfunctional)	Pancreas (body)
12	63	M	Pancreatic cancer	Pancreas (head)
13	64	M	Pancreatic cancer	Pancreas (body)
14	69	M	Pancreatic cancer	Pancreas (head)
15	71	F	Pancreatic cancer	Pancreas (body)
16	72	F	Pancreatic cancer	Pancreas (body)
17	72	F	Pancreatic cancer	Pancreas (head)
18	75	M	Pancreatic cancer	Pancreas (head)
19	76	M	Duodenal cancer	Pancreas (head)
20	27	F	Insulinoma	Insulinoma
21	23	F	Glucagonoma	Glucagonoma
22	41	F	Acinar cell tumor	Acinar cell tumor
23	34	F	Glucagonoma	Glucagonoma

Patients were premedicated with 0.01 mg/kg atropine sulfate i.m. and 0.2 mg/kg diazepam orally before surgery. Tissues were sampled under general

anesthesia with 35% O₂, 65% N₂O and 0.5-1.5% sevoflurane. Neuromuscular blockade was provided by vecuronium bromide at an initial dose 0.1 mg/kg and supplemented as required.

Table 2. The metabolic parameters and the levels of GPR119 mRNA in the pancreas of 19 patients

Patient	BMI (kg/m ²)	FPG (mmol/l)	2h-PG (mmol/l)	Insulin (×10 ³ pmol/l)	AUC	HbA1c (%)	HOMA-IR	Insulinogenic index	HOMA- beta	Triglycerides (mmol/l)	GPR119 mRNA level
1	24.2	4.7	6.7	32		5.1	9.6	83.0	124.4	1.23	0.183
2	19.7	7.2	12.6	53		7.1	36.6	100.1	102.1	2.26	0.334
3	17.7	4.4	6.8	24		5.1	2.8	62.7	50.8	1.54	0.430
4	22.3	4.9	9.1	18		5.7	3.7	17.8	40.3	0.89	0.112
5	24.6	5.1	8.3	25		5.1	5.7	42.8	54.0	1.20	0.235
6	25.7	6.1	ND	ND		5.6	24.0	ND	112.60	1.48	0.342
7*	22.1	2.0	4.9	84		4.7	2.5	ND	-61.3	0.86	0.419
8	18.0	5.3	10.8	12		6.3	3.3	23.6	25.1	1.76	0.063
9	19.6	4.3	11.4	ND		5.4	2.0	ND	40.8	2.01	0.228
10	20.0	4.6	6.9	24		5.0	8.4	163.7	130.7	1.40	0.583
11	22.8	5.5	13.6	ND		6.7	8.5	ND	58.0	2.28	0.483
12†	24.2	4.8	ND	ND		6.5	ND	ND	ND	1.01	0.582
13	23.3	5.2	10.7	18		5.8	8.5	11.1	70.8	1.29	0.185
14	24.3	ND	ND	ND		7.1	ND	ND	ND	0.95	0.272
15	23.5	4.9	8.9	ND		6.2	10.3	ND	113.8	1.99	0.492
16	18.4	6.1	ND	ND		6.5	ND	ND	ND	2.03	0.306
17†	16.8	5.1	ND	ND		5.8	ND	ND	ND	1.02	0.631
18	22.6	5.4	8.3	51		6.2	6.8	47.8	48.3	1.60	0.219
19	20.3	4.2	6.8	48		5.4	3.0	103.1	81.0	0.49	0.279

The patient numbers correspond to those in Table 1. *Patient 7 was diagnosed as having an insulinoma. †Patients 12 and 17 were treated with percutaneous transhepatic biliary drainage (PTBD). Because of the unavailability of blood samples, some of the metabolic profiles were not determined (shown as *ND*). *FPG*, fasting plasma glucose level; *2h-PG*, 2-h post-OGTT plasma glucose level; *ND*, not determined

Table 3. GPR119 mRNA levels in various regions of the pancreas in humans

Pancreatic region(s)	GPR119 mRNA level	<i>n</i>	<i>p</i> *
Head	0.372 ± 0.052	11	-
Body	0.294 ± 0.069	6	0.388
Tail	0.262 ± 0.079	2	0.367
Body and tail	0.286 ± 0.053	8	0.264

GPR119 mRNA levels are expressed as means ± SEM. Comparisons were made using unpaired two-tailed *t*-tests. **p* values are *vs* the head.

Supplemental Table S1: Correlation between pancreatic GPR119 mRNA levels and various clinical parameters

	<i>n</i>	<i>r</i>	<i>p</i>
Age	19	0.290	0.256
BMI	19	0.017	0.597
FPG	15	0.0001	0.967
2h-PG	13	0.005	0.825
Insulin-AUC	10	0.042	0.570
Triglyceride	19	0.0004	0.939
HbA1c	10	0.109	0.350
HOMA-IR	14	0.000048	0.981
	10	0.039	0.583
	14	0.047	0.454

The correlations between pancreatic GPR119 mRNA levels and various parameters were examined using simple regression analysis. FPG, fasting plasma glucose level; 2h-PG, 2-h post-OGTT plasma glucose level.